Table: New Pharmacological Drug Classes Introduced in 2008

Pharmacologic Class	First to be Marketed in the U.S.	FDA Approved Indication
C1 inhibitor	C1 inhibitor(CinryzeR)	Routine prophylaxis against angioedema attacks in patients with hereditary angioedema
CXCR4 chemokine receptor inhibitor	plerixa (MozobilR)	Mobilization of granulocyte-colony stimulating factor induced hematopoietic stem cells to the peripheral blood prior to collection